Imunon

IMNN · NASDAQ

$1.01+$0.02 (+2.03%)TodayMarket closed · Oct 20, 4:00 PM ET

Prev close $0.985

IMNN analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $17.34 (+1625.4% upside)

Low: $10.10
Now: $1.01
High: $26.25

Upgrades and downgrades

The latest rating actions, newest first

IMNN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Maxim Group	Apr 17, 2026	Initiates	Buy	$10.00	27%

The case for and against

Updated Oct 31, 2025

Bull case

Imunon Inc demonstrated substantial progress in its clinical pipeline during the first quarter of 2025, marked by the initiation of the OVATION 3 trial, which reflects the company's commitment to advancing innovative treatments. The company is leveraging positive translational and survival data from its Phase 2 OVATION 2 study to launch a targeted registrational effort aimed at addressing significant unmet medical needs in frontline ovarian cancer therapy. This strategic focus not only highlights Imunon's potential for impactful advancements in cancer treatment but also positions the company favorably within the biopharmaceutical industry.

Bear case

Imunon Inc's financial position is a significant concern, highlighted by a cash balance of only $2.9 million as of March 31, 2025. The company is anticipated to require a series of dilutive financings that may occur sooner and under less favorable terms than previously expected. This precarious financial state raises doubts about the company's ability to sustain its operations and advance its clinical programs without substantial funding challenges.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.